Nilotinib
Peritoneal Neoplasms
National Cancer Institute (NCI)Small moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
17 Active assets in the Peritoneal Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Eli Lilly and Company | Phase 3 | BBB |
Inno-206 Eli Lilly and Company | Phase 3 | BBB |
FLUOROURACILUM AstraZeneca | Phase 2 | BB |
Eloxatin Sun Yat-sen University | Phase 2/3 | BB |
Patupilone Novartis Pharmaceuticals | Phase 3 | BB |
View all 44 →
Same molecule, other indications
Nilotinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
74 / 100
View asset →blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →